印度制药公司Wockhardt
Wockhardt Limited India,成立于1960年，印度最大的医药和生物科技企业，该公司提供包括药物配方，营养素产品和疫苗，活性药物成份，以及生物制药等领域的产品和服务。截止到2005年底该公司共有大约3500名员工，其中大约500名员工供职于海外分支机构。Wockhardt还是印度唯一获得“超级品牌”称号的医药企业，该称号由国际组织“超级品牌理事会”颁发。

Wockhardt 和许多重要的制药公司诸如Aventis, Amylin 以及 Astra Zeneca等组成了战略联盟。它在印度和英国都有分公司，这些分公司都接受美国FDA和英国MHRA的认证。

Preparing for change before change beckons. Harnessing the power of innovative research. Providing high-quality medicines for a healthier world. This is our world at Wockhardt.
Wockhardt is a global, pharmaceutical and biotechnology company that has grown by leveraging two powerful trends impacting the world of medicine - globalisation and biotechnology.

The Company has a market capitalisation of over US$ 1 billion and an annual turnover of US$ 650 million. Wockhardt’s pace of growth and momentum permeates every mindset, system and technology within the organisation.

Wockhardt today, is distinguished by a strong and growing presence in the world’s leading markets, with more than 65% of its revenue coming from Europe and the United States. Wockhardt’s market presence covers formulations, biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (APIs).

The Company has its headquarters in India, and has
14 manufacturing plants in India, UK, Ireland, France and US
Subsidiaries in US, UK, Ireland and France
Marketing offices in Africa, Russia, Central and South East Asia.
 

Wockhardt has a strong track record in acquisition management, with five successful acquisitions in the European market. These acquisitions have strengthened Wockhardt’s position in the high-potential markets of Europe, and have expanded the global reach of the organisation.

Wockhardt Advantage

Wockhardt’s manufacturing facilities in India, UK, Ireland, France and US have the approval of major regulatory bodies, including US FDA and UK's MHRA, with capabilities for both Finished Dosage Formulations and APIs. The output includes

Steriles (Injectables)
Biopharmaceuticals
Orals (Tablets & Liquids)
Topicals (Creams & Ointments).

Wockhardt is a partner of choice for manufacturing, having entered into manufacturing alliances with leading pharmaceutical and biotechnology majors, including

Astra Zeneca Lab Aguettant
Aventis Amylin
Schering-Plough Eisai
Cell Therapeutics LSI, UK
AFT, New Zealand Ebewe, Austria

A key growth driver at Wockhardt is its state-of-the-art, multi-disciplinary research capability backed by a team of 500 skilled scientists. Consistent efforts have resulted in six breakthrough biotechnology products, 750+ patent filings and a pipeline of promising new molecules.

Wockhardt’s strategies are aligned towards being a significant player in the emerging global biopharmaceuticals market. In order to achieve this goal, the company has set up the Wockhardt Biotech Park, India’s largest biopharmaceuticals complex, with six dedicated plants built to international standards.